CML
News
Cancer cell lines predict drug response, study shows
Image from PNAS A study published in Cell has shown that patient-derived cancer cell lines harbor most of the same genetic changes found in...
News
NICE recommends approval for bosutinib
Photo courtesy of CDC The National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending approval for...
News
Drugs produce comparable results in CP-CML
Long-term results from the DASISION trial suggest that dasatinib and imatinib produce similar outcomes in patients with newly diagnosed chronic...
News
Study: CMV doesn’t lower risk of relapse, death
Small studies have suggested that early cytomegalovirus (CMV) reactivation may protect against leukemia relapse and even death after hematopoietic...
News
Team describes method of targeting LSCs in BC-CML
Photo courtesy of UC San Diego Health New research has revealed a method of targeting leukemia stem cells (LSCs) in blast crisis chronic myeloid...
Conference Coverage
Stopping TKI therapy can be safe, study suggests
COPENHAGEN—Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic...
News
How CML cells respond to stress
Image by Difu Wu Researchers have used a tiny force probe to compare how healthy hematopoietic cells and cancerous ones respond to stress. They...
Conference Coverage
Hold that TKI – When it’s safe to stop in CML
Key clinical point:.Tyrosine kinase inhibitor therapy can be safely stopped and resumed in many patients with chronic-phase chronic myeloid...
News
Tyrosine kinase inhibitors may boost cardiac risk in chronic myeloid leukemia
Tyrosine kinase inhibitors were associated with a significantly increased risk of cardiovascular events among chronic myeloid leukemia patients....
Conference Coverage
Most CML patients who stop nilotinib stay in remission
CHICAGO—Nearly 60% of chronic myeloid leukemia (CML) patients who switch to nilotinib from imatinib maintain treatment-free remission for 48 weeks...